TY - PAT
T1 - Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin
AU - Dijkstra, Gerard
AU - Faber, Klaas Nico
AU - Bourgonje, Arno Rolf
AU - Gabriëls, Ruben Yannick
AU - von Martels, Julius Zweder Hubertus
PY - 2020/11/12
Y1 - 2020/11/12
N2 - The invention relates generally to biomarkers, methods and kits to predict therapy response in patients, in particular in patients having inflammatory bowel disease (IBD). Provided is a method for predicting whether a human subject is likely to show a clinical response to therapy with an antibody or pharmacological antagonist that targets α4β7 integrin, preferably vedolizumab induction therapy, comprising (i) determining the level of eotaxin-1 in a sample obtained from the subject, and; (ii) classifying the subject as a responder based on the leve of eotaxin-1.
AB - The invention relates generally to biomarkers, methods and kits to predict therapy response in patients, in particular in patients having inflammatory bowel disease (IBD). Provided is a method for predicting whether a human subject is likely to show a clinical response to therapy with an antibody or pharmacological antagonist that targets α4β7 integrin, preferably vedolizumab induction therapy, comprising (i) determining the level of eotaxin-1 in a sample obtained from the subject, and; (ii) classifying the subject as a responder based on the leve of eotaxin-1.
M3 - Patent
M1 - WO2020226498
Y2 - 2020/05/07
ER -